Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
NCT07247266

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Led by Akros Pharma Inc. · Updated on 2026-02-09

5

Participants Needed

1

Research Sites

43 weeks

Total Duration

On this page

Sponsors

A

Akros Pharma Inc.

Lead Sponsor

P

PPD Development, LP

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)

CONDITIONS

Official Title

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with familial cold autoinflammatory syndrome (FCAS) or Muckle-Wells syndrome (MWS) confirmed by clinical history with at least 2 typical symptoms prior to screening and confirmed NLRP3 mutation
  • Willing to discontinue current anti-interleukin-1 treatment if applicable
  • Shows new flare-up of CAPS symptoms during screening period
Not Eligible

You will not qualify if you...

  • Has chronic infantile neurologic cutaneous articular syndrome (CINCA)/neonatal-onset multisystem inflammatory disease (NOMID)
  • History or presence of amyloidosis, progressive hearing loss, organ damage, or any symptom that prevents stopping anti-IL-1 treatment
  • Active systemic bacterial, fungal, or viral infection within 14 days before Day 1 or history of significant recurrent infections

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Gordon Sussman Clinical Research Inc.

North York, Ontario, Canada, M3B 3S6

Actively Recruiting

Loading map...

Research Team

T

Takanori Nemoto, M.S.

CONTACT

K

Kala Patel, R.Ph., RAC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) | DecenTrialz